2Guy JR, Fagien S, Donovan JP, et al, Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy, Ophthalmology,1989, 96 (7): 1048-1052.
3Kauppinen-Makelin R, Karma A, Leinonen E, et al, High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid - associated ophthalmopathy. Acta Ophthalmol Scand,2002, 80 (3): 316-321.
4Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves' ophttmlmopathy: a novel approach. Br J Ophthalmol, 1989, 73:639-644.
5Wiersinga WM, Prummel MF. Graves' ophthalmopathy: a rational approach to treatment. Trends Endocrinol Metab, 2002, 13:280-287.
6Evans RM.The steroid and thyroid hormone receptor superfamily.Science,1998,240:889-895.
7Bamberger CM,Schulte HM,Chrousos GP.Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids.Endocr Rev,1996,17:245-261.
8Hollenberg SM,Weinberger C,Ong ES,et al.Primary structure and expression of a functional human glucocorticoid receptor cDNA.Nature,1985,318:635-641.
9Bieche I,Onody P,Laurendeau I,et al.Real-time reverse transcription-PCR assay for future nagement of ERBB2-based clinical apolications.Clin Chem,1999,45:1148-1156.
10Oakley RH,Webster JC,Sar M,et al.Expression and subcellular distribution of the β-isoform of the human glucocorticoid receptor.Endocrinology,1997,138:5028-5038.
